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ABSTRACT
A JOINT LONGITUDINAL-SURVIVAL MODEL WITH POSSIBLE CURE: AN
ANALYSIS OF PATIENT OUTCOMES ON THE LIVER TRANSPLANT
WAITING LIST
Arwin M. Thomasson
Sarah J. Ratcliffe
Data from transplant patients has many unique characteristics that can cause prob-
lems with statistical modeling. The patient’s underlying disease / health trajectory
is known to affect both longitudinal biomarker values and the probability of both
death and transplant. In liver transplant patients, biomarker values show a sharp
exponential increase in the days preceding death or transplant. Patients who receive
transplants show an immediate drop in biomarker values post-transplant, followed by
an exponential decrease. Patients’ survival probabilities also change post-transplant,
with dependencies on pre-transplant biomarker values. To properly incorporate these
clinical features, we developed a joint longitudinal-survival model that links an ex-
ponential growth-decay longitudinal model to a modified cure survival model. This
allows us to evaluate patient biomarker trajectories and survival times both pre- and
post-transplant. The models are linked by patient-level shared random effects that
appear in the biomarker trajectories and the frailties of the survival functions. Esti-
mates are obtained via the EM algorithm, with random effects integrated out of the
complete data likelihood function using adaptive quadrature techniques. Simulations
show our model performs reasonably well under a variety of conditions. We demon-
strate our methods using liver transplant data from the United Network of Organ
iv
Sharing (UNOS). We use total serum bilirubin as our longitudinal outcome, with age
at waitlisting and gender as linear covariates. Gender is used as a covariate in the
survival model both pre- and post-transplant.
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CHAPTER 1
Introduction
Transplant waiting list data is a relatively new resource to researchers. National
transplant registry data was not collected until 1987. (Contrast this with other stud-
ies, such as the United States census, the Framingham Heart Study, and the Nurses’
Health Study, which began in 1790, 1948, and 1976, respectively.) In 1984, Congress
passed the National Organ Transplant Act (NOTA). NOTA created the national
transplant registry, which is now called the Organ Procurement and Transplantation
Network (OPTN). The United Network of Organ Sharing (UNOS) was given a federal
contract in 1986 to manage OPTN. More detailed information can be found on the
OPTN website (http://optn.transplant.frsa.gov).
This registry (henceforth known as the UNOS registry) contains data about all pa-
tients who are waitlisted for an organ transplant. This data includes both demo-
graphic and medical information. Each organ has its own set of relevant biomarker
values which can be used to measure organ function and can serve as surrogates to
indicate underlying illness and overall health status. For example, on the liver trans-
plant waiting list, patients’ bilirubin levels are collected to measure liver function. In
contrast, forced vital capacity (FEV) is used to assess the lung function of patients
on the lung transplant waiting list.
Transplant data have many interesting features that can present challenges with sta-
tistical methods typically used to analyze transplant data. It is reasonable to hy-
pothesize that patients’ longitudinal biomarker values are related to survival times
in complex ways. Sicker patients may be more likely to die or be removed from the
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waiting list. Healthier patients may be passed over for transplants in favor of giving
organs to others in a more critical situation. This relationship is not necessarily ac-
knowledged in simple statistical analyses. A more complex model is often required
to properly analyze this data. Joint statistical models that incorporate “informative
dropout” are more appropriate for analyzing this type of data (Little and Rubin,
1987).
Transplant data has additional complications that cause issues even when joint mod-
els are used to account for informative dropout. For example, some (but not all) of
the patients on the waiting list for an organ will receive a transplant. Transplant
is expected to change a patient’s survival time (i.e. transplant changes a patient’s
relative hazard of death). This violates the key assumption of constant relative haz-
ards in the Cox proportional hazard model, commonly used to model patient survival
times (e.g. Wulfsohn and Tsiatis, 1997; Hsieh et al., 2006).
In this dissertation, we develop a joint longitudinal-survival model that addresses
these challenges of modeling transplant data. This new model allows for non-linear
biomarker trajectories, as well as the possibility of patient health improvement via
transplant. Use of a two-part survival model avoids the assumption of non-constant
relative hazards in patients who receive transplants.
1.1. Modeling transplant data
Transplant data has many characteristics that make it somewhat difficult to model.
Researchers must consider the impact of inclusion/exclusion criteria, censoring pro-
cesses, possible cure via medical intervention, and missing longitudinal data. Though
these issues do show up in other types of studies, they do not often appear simulta-
neously.
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Figure 1.1: Survival outcomes
Added to waitlist No transplant 
Censored at end of study 
Transplant 
Censored at end of study 
Transplant 
Died before end of study 
Transplant
Censored before end of study 
No transplant 
Censored before end of study 
No transplant 
Died before end of study 
After patients are placed on the transplant waiting list, they can experience a variety
of different outcomes (illustrated in Figure 1.1). Patients may or may not receive
a transplant, and patients can either die or be censored from the study. This gives
us four different outcome possibilities: died before receiving transplant, censored
before receiving transplant, died after receiving transplant, or censored after receiving
transplant.
Patients can leave the study for “random” or “non-random” reasons. For example,
a patient may move far away and have to switch care providers. This would be
considered a random dropout, since the patient’s decision to move is likely unrelated
to his disease process. In contrast, a patient could stop participating in the study
because he is too sick to make it to his follow-up appointments. This would be
considered non-random since the patient’s reasons for dropout are directly related to
his disease process. A more in-depth discussion of the implications of patient dropout
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can be found in Chapter 2.
In studies of transplant data, researchers often focus primarily on pre- or post-
transplant data, but not both (Merion et al., 2003; Crowley and Hu, 1977). This
is not necessarily the best study design. It is possible that healthier patients or pa-
tients with other desirable characteristics (e.g. a common blood type) are more likely
to be selected for transplant (Crowley and Hu, 1977). These patients are therefore
more likely to be censored in a pre-transplant study, and are more likely to enroll in a
post-transplant study. Assuming random patient dropout is clearly not appropriate
here. Care must be taken when setting up study assumptions, as incorrect assump-
tions about patients’ dropout processes could change inference results (Heitjan, 1993).
Another potential pitfall arises in the fact that pre-transplant risk factors can affect
post-transplant outcomes. Baliga et al. (1992) showed that pre-transplant factors,
such as the need for pre-transplant dialysis, are associated with poor post-transplant
outcomes, such as a higher risk of post-transplant sepsis and death. A common
method of incorporating pre-transplant data into post-transplant analysis is to in-
clude summary measures of pre-transplant activity. For example, Hariharan et al.
(2002) and Chertow et al. (1996) considered pre-transplant interventions (e.g. blood
transfusions and dialysis) and panel reactive antibody (PRA) levels in the recipient
(a measure of immune response) as potential factors affecting post-transplant out-
comes. Although proper in intent, this strategy does not capture the changes in
patient biomarker values. These changes may be of interest in pre-transplant studies
as well as post-transplant studies. Merion et al. (2003) showed that the rate of change
in a patient’s liver function is an important predictor of mortality on the waiting list.
Wu et al. (2010) demonstrated that the slope of changes in post-transplant renal
function is predictive of graft survival. It is reasonable to suspect that pre-transplant
4
biomarker trajectories could be related to post-transplant outcomes. At this time,
models that incorporate these trajectory features have not been developed.
Additional complications arise when the goal of a study is to compare pre- and post-
transplant outcomes. A commonly-used method is to model the data as two separate
cohorts. Bloom et al. (2005) demonstrated this process. Analysis of pre-transplant
mortality is assessed using all patients’ pre-transplant data. Patients in this group
are censored at the time of transplant. Post-transplant mortality is then analyzed
using post-transplant data from any patient who received a transplant. Though this
method allows for the comparison of pre- and post-transplant survival outcomes, it
ignores the fact that the two analysis groups overlap. Since they contain some of the
same patients, they are likely not completely independent.
To properly analyze patient survival times, we must acknowledge two issues. First,
patients who receive transplants can still die, but they are presumably less likely to
die post-transplant than those patients who do not receive transplants. Second, not
all patients will receive transplants. Law et al. (2002) and Li et al. (2010) assumed
that each patient had some probability of being cured by treatment. The survival
times for patients who were not cured were modeled using a Cox proportional hazards
model. These cure models allow for the potential difference in survival probabilities for
patients who are cured. Unfortunately, cure models make some assumptions that are
inappropriate for transplant data. First, cure models assume that all patients receive
the treatment. Second, these models assume that patients who are “cured” cannot
die from the disease being treated (Baker, 1978). Therefore, standard cure models
do not allow for us to draw conclusions about pre- and post-transplant survival, nor
will they allow us to compare treated and untreated patients.
Like most longitudinal analyses, studies using transplant data have to overcome the
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problem of missing data. Authors use a variety of approaches to deal with the problem
of patient dropout in longitudinal studies of transplant data. Fann et al. (2002) and
Felder-Puig et al. (2006) used multiple imputation (MI) to analyze data from adult
and pediatric bone marrow transplant patients, respectively. MI relies on relationships
between the variables in the dataset. For example, suppose we have a simple dataset
that contains a patient’s weight, height, and age. For patients with missing values for
height, we could use MI to predict the missing height values using patients’ weights
and/or ages. MI methods are useful tools when neither the dropout mechanism nor
the actual missing values are of interest (Little and Rubin, 1987). In the case of
transplant data, however, we are interested in both the dropout process (death) and
the missing data (potential future biomarker values).
Another method used to deal with missing data is last observation carried forward
(LOCF) (Pocock, 1984). LOCF imputes a subject’s missing observations with the last
observed value for that subject. Clearly, this method has a high potential for improper
inference. Biased parameter estimates and underestimated variance are particular
problems. (Saha and Jones (2009) discussed these issues in depth.) Furthermore, like
MI, LOCF does not allow for inference about the dropout process or the missing data
values.
Joint models, which allow for inference about both submodels, are needed. These
models are discussed in detail in Chapter 2.
1.2. Liver transplant data
UNOS is a widely-used source of transplant data. When subjects are initially wait-
listed for an organ transplant, they are entered into the UNOS database. Patient
records are updated occasionally, with the frequency of updates depending on the
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type of organ. For liver transplant patients, UNOS requires updates with varying
frequency, based upon patients’ Model for End-Stage Liver Disease (MELD) scores.
MELD scores are used to predict 90-day mortality for patients on the liver transplant
waiting list, with higher scores indicating a higher probability of death (Wiesner et al.,
2003). UNOS uses this information to rank patients and determine liver distribution
policies (Kamath et al., 2001).
The MELD score combines three different biomarker values: serum creatinine (Cr),
serum total bilirubin (TBIL), and the international normalized ratio of prothrombin
time (commonly referred to as INR). MELD scores are calculated using the following
formula:
MELD = 3.78 · log [TBIL] + 11.2 · log [INR] + 9.57 · log [Cr] + 6.43
Any MELD component with a value of less than 1 is replaced with 1, to prevent
negative scores. Adjustments are also made for patients who have been on dialysis
in the past week. For those patients, 4.0 is used as the value for serum creatinine.
MELD scores are rounded to the nearest whole integer, and are capped at a value of
40.
MELD scores are used to predict pre-transplant survival times of patients and are
unfortunately not validated for use post-transplant. Since we are interested in both
pre- and post-transplant data, we have chosen to use a single component of the
MELD score, bilirubin, for our analysis. INR, serum creatinine, or another continuous
biomarker could also be a valid longitudinal outcome.
A potential source of bias in the data comes from the fact that MELD scores (and
therefore bilirubin, INR, and creatinine values) are, by law, updated more often for
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sicker patients (UNOS, 2002). To avoid this bias, we limited the analysis to pa-
tients for whom we could augment the UNOS data with data from the Hospital of
the University of Pennsylvania (HUP). This gives us more observations per subject,
regardless of health status. We collected data from all patients waitlisted at HUP
between February 27, 2002, and May 13, 2011. The start date was chosen because
that is the day on which UNOS began using MELD scores to rank all patients on the
waitlist. Data are collected more consistently after that point. Our initial dataset
consisted of 1,387 patients, each with a minimum of four observations. Patients who
did not receive transplants were followed for a maximum of five years. Patients who
received transplants were followed either for five years post-waitlisting, or from time
of waitlisting until three years post transplant, whichever came first.
Samples of this data were used to demonstrate the methods in Chapters 3 and 4.
Demographic and baseline summaries of these samples are given in Tables 3.4 and
4.4.
1.3. Discussion
The unique characteristics of transplant data clearly require the use of advanced
statistical techniques that allow for a link between longitudinal and survival outcomes.
In this dissertation, we develop a method for combining longitudinal and survival data
in the presence of possible patient cure. Using a shared parameter model, we link
the longitudinal and survival submodels via random effects that appear in both the
subject-specific longitudinal trajectories and survival frailties.
In this chapter, we have outlined the unique issues associated with transplant data,
as well as some authors’ attempts to analyze it. We have also provided a discussion
of the need for joint modeling of data with informative dropout.
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In the remainder of this dissertation, we develop a joint longitudinal-survival model
to analyze liver transplant data. Chapter 2 gives a thorough background of the issue
of informative dropout and what statistical models can be used to compensate for it.
Chapter 3 develops an initial joint model, where patients are assumed to be cured
post-transplant. Chapter 4 extends the model in Chapter 3 to include the possibility
of post-transplant death. We demonstrate our methods using liver transplant data
from the United Network of Organ Sharing and the Hospital of the University of
Pennsylvania. Chapter 5 summarizes the methods developed and the implications for
the analysis of transplant data.
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CHAPTER 2
Informative Dropout
Missing data is a challenge that exists in almost every kind of study. The validity
of many standard longitudinal analysis methods depends on the randomness of the
dropout process (Diggle et al., 2002). In real data, this may or may not be the case.
Missingness can occur due to several different processes, each of which has different
implications for the statistical analysis of the data.
2.1. Missingness patterns
Missingness can be classified as missing completely at random (MCAR), missing
at random (MAR), or not missing at random (NMAR). These patterns are defined
by what portions (if any) of the observed data are dependent on the missing data
(Rubin, 1976). Let Y be the complete data. We can then divide Y into two subsets:
the observed data Yobs and the unobserved data Ymiss. R is a vector of indicator
variables describing the missingness pattern of the data. Let fY (Yobs,Ymiss) be the
probability density function (PDF) of Y and fR (R | Yobs,Ymiss) be the missingness
process.
We can write the joint PDF of Y and R as
fY,R (Yobs,Ymiss,R) = fY (Yobs,Ymiss) fR (R | Yobs,Ymiss) (2.1.1)
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We integrate the missing data out of the full PDF.
fYobs,R (Yobs,R) =
∫
fY,R (Yobs,Ymiss,R) dYmiss
=
∫
fY (Yobs,Ymiss) fR (R | Yobs,Ymiss) dYmiss (2.1.2)
This gives us the PDF for the observed data.
2.1.1. Missing completely at random
If the data are MCAR, the missingness process depends on neither the observed nor
the missing data. This gives us the following simplification for (2.1.2).
fYobs,R (Yobs,R) =
∫
fY (Yobs,Ymiss) fR (R | Yobs,Ymiss) dYmiss
=
∫
fY (Yobs,Ymiss) fR (R) dYmiss
= fR (R)
∫
fY (Yobs,Ymiss) dYmiss
= fR (R) fY (Yobs) (2.1.3)
Maximum likelihood theory seeks to maximize the likelihood with respect to our data,
so maximizing (2.1.3) with respect to Yobs is equivalent to maximizing
f ∗Yobs,R = C · fY (Yobs) (2.1.4)
where C is a constant. This is true because fR (R) does not depend on Yobs. There-
fore, if the data are MCAR, all standard longitudinal methods can be used. This
kind of missingness is considered “ignorable”.
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2.1.2. Missing at random
For MAR data, the missingness process can depend on Yobs, but not on Ymiss. This
more relaxed assumption still allows us to simplify (2.1.2), though not quite as much
as with MCAR data.
fYobs,R (Yobs,R) =
∫
fY (Yobs,Ymiss) fR (R | Yobs,Ymiss) dYmiss
=
∫
fY (Yobs,Ymiss) fR (R | Yobs) dYmiss
= fR (R | Yobs)
∫
fY (Yobs,Ymiss) dYmiss
= fR (R | Yobs) fY (Yobs) (2.1.5)
Missingness in MAR data is still considered to be “ignorable”. Diggle et al. (2002)
noted that standard likelihood-based longitudinal analyses, such as generalized linear
mixed models, can still be used with MAR data, though there is a potential for a loss
in efficiency. Analyses that rely on other methods of estimation, such as generalized
estimating equations (GEE), cannot be used. Using GEE with MAR data can lead
to parameter estimates with a bias as high as 50% (Touloumi et al., 2001).
2.1.3. Not missing at random
If data are NMAR, the missingness process depends on both Yobs and Ymiss. No
simplification can be made to (2.1.2). This missingness is considered “non-ignorable”
or “informative”. NMAR data requires the use of a joint longitudinal-missingness
model in order to obtain proper parameter estimates.
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2.2. Analysis methods
Little and Rubin (1987) defined four broad (somewhat overlapping) classes of proce-
dures used to compensate for missing data.
1. Complete-case analysis
Complete-case analysis is a very straightforward method of dealing with missing
data. Subjects with any missing data are simply excluded from analysis. This
simplicity comes at a cost, however. Little and Rubin (1987) noted that the
loss of information from excluded subjects can result in less precise estimates,
or, even worse, severe bias in parameter estimates.
2. Probability weighting
Probability weighting treats the missing data patterns as if they were part of the
sampling design. The data are then analyzed using methods similar to standard
stratified analysis. Chand and Rothwell (1977) give an example of a standard
stratified data analysis. Slight changes must be made to “true” stratified analysis
methods to account for increased variance (since the sampling weights are not
actually fixed by design). There is also still a potential for estimate bias, if the
data are NMAR (Little and Rubin, 1987).
3. Missing-value imputation
Imputation methods “fill in” missing data values using fully-observed data. Last
observation carried forward (LOCF) and multiple imputation (MI), discussed
in Section 1.1, are two examples of imputation procedures. Imputation meth-
ods have many of the same pitfalls as complete-case methods. If the data are
NMAR, parameter estimates are subject to bias (Lavori et al., 1995; Sterne
et al., 2009) and incorrect standard errors (Lavori et al., 1995).
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4. Model-based procedures
Model-based missing data analysis requires the specification of a model for both
the outcome and the missingness process (Little and Rubin, 1987). A variety
of model-based procedures are discussed in the remainder of this chapter.
Methods for dealing with NMAR data arose out of the need for proper study design
and data analysis in longitudinal trials. In many of these trials, it is reasonable
to suspect that patient dropout could depend on patients’ longitudinal outcomes.
For example, the outcome for the Intermittent Positive Pressure Breathing (IPPB)
trial was patients’ longitudinal measurements of forced expiratory volume (FEV).
Wu and Carroll (1988) showed that dropout from the IPPB trial was not random.
Patients with low initial FEVs or rapid rates of decline in FEV were more likely to
die. Similar issues were encountered in the Modification of Diet in Renal Disease
(MDRD) trial. The outcome for the MDRD trial was patient kidney function, as
measured by glomerular filtration rate (GFR). Patients with very low GFRs were
more likely to be removed from the study due to death, beginning dialysis, or kidney
transplant (Beck et al., 1991). Similar challenges are encountered when analyzing
data from many different areas of study, including AIDS (De Gruttola and Tu, 1994),
opiate addiction (Follmann and Wu, 1995), pain relief (Pulkstenis et al., 1998), and
prostate cancer (Law et al., 2002).
There are two standard classes of joint models: selection and pattern-mixture models.
The types of models differ with respect to which parts of the complete-data likelihood
are conditional and which are marginal. For the following discussion, we assume
that we have data with repeated longitudinal observations, Yobs, and dropout time
information, t. Dropout is governed by some random process R.
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2.2.1. Pattern-mixture models
Pattern-mixture models assume that patient longitudinal outcomes are conditional
on the drop-out process (Little, 1993). Analysis is done by stratifying subjects on
dropout time and combining the within-stratum models to form an overall marginal
longitudinal model.
fYobs,t (Yobs, t) =
∫
fY (Yobs | t,R) fR (R | t) ft (t) dR (2.2.1)
This model is robust to misspecification, though it has the consequence of modeling
the longitudinal data as conditional on the dropout process. This is a reasonable
strategy in some cases, in particular when dealing with survey non-response. With
non-response, we generally assume that patients with similar patterns of responses to
some survey questions will have similar responses to other survey questions. There-
fore, we can use the information from subjects with fully-observed responses to “fill
in” the subjects with missing data. This is the justification for the method of multiple
imputation, where the fully-observed data is used to predict the values for the missing
data (Little and Rubin, 1987).
Conditioning the longitudinal model on future dropout is not always reasonable,
though, particularly if the end goal of analysis is to develop a predictive model.
In a predictive model, the subject’s dropout time would be some unknown future
event. A pattern-mixture model would clearly be unreasonable in a predictive model,
since we would be attempting to predict an unknown outcome based on an unknown
predictor (future dropout time). This model also prevents us from explicitly modeling
the dropout process. The dropout process may be of interest if, for example, subject
dropout is related to subject survival times.
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2.2.2. Selection models
Selection models assume the drop-out process is conditional on patient longitudinal
outcomes. Results are obtained by modeling the available data and adding on a
conditional missingness model (Laird and Ware, 1982).
fYobs,t (Yobs, t) =
∫
fY (Yobs) ft (t | Yobs,R) fR (R) dR (2.2.2)
Selection models have the advantage of not conditioning analysis on future, unknown
dropout times. However, they are not robust to violations of the assumption of normal
longitudinal errors, or to misspecification of the dropout process (Little and Rubin,
1987).
2.2.3. Shared-parameter models
Shared-parameter models are a specific case of selection models. They have become
a very popular method of dealing with informative dropout. Shared-parameter mod-
els treat the longitudinal and survival submodels as conditionally independent given
underlying shared random effects. These random effects contribute to both the lon-
gitudinal and survival portions of the model (Ratcliffe et al., 2004).
fYobs,t (Yobs, t) =
∫
fY (Yobs | R) ft (t | R) fR (R) dR (2.2.3)
The conditional independence assumption means that shared-parameter models are
fairly straightforward to understand and explain. Both the longitudinal trajectories
and dropout processes can be modeled explicitly. The longitudinal trajectories and
dropout processes can, in theory, be modeled using any type of statistical submodel.
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Several specific combinations have been proposed.
Early work with shared-parameter models focused on joint models with tractable,
closed-form parameter estimates. Schluchter (1992) and De Gruttola and Tu (1994)
employed multivariate normal models for patient biomarker trajectories and a one-to-
one normalizing transformation of patient survival times. Both authors assumed that
the shared random effects are normally distributed. This allowed for straightforward
calculation of parameter estimates thought the use of the EM algorithm (Dempster
et al., 1977).
Both authors modeled patient biomarker values using a standard linear mixed effects
model:
Y i =X iα+Ziri + "i (2.2.4)
where "i ∼ N (0, σ2!Ii), X i and Zi are both known, subject-specific design matrices,
and α and ri are vectors of unknown fixed and random parameters, respectively.
Transformed patient survival times were also modeled using a random effects model:
Ti = w
T
i ζ + λri + τi (2.2.5)
where τi ∼ N (0, s2), wi is a known design vector, ζ and λ are unknown fixed param-
eters, and ri is the shared link between this survival time model and (2.2.4) above.
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These models give the following observed-data likelihood:
Lobs =
n∏
i=1
[∫
ri
φ
(
Y i | ri,α, σ2!
) (
φ
(
ti | ri, ζ,λ, s2
))δi=1
× (1− Φ (ti | ri, ζ,λ, s2))δi=0 φ (ri) dri] (2.2.6)
where ti is the minimum of a patient’s death (Ti) and censoring (Ci) time, δi is
an indicator for death (1) or censoring (0), and n is the total number of subjects.
φ (·) and Φ (·) are the PDF and cumulative density function (CDF) of the normal
distribution, respectively.
Other authors have extended the methods proposed by Schluchter (1992) and De Grut-
tola and Tu (1994) to include non-linear longitudinal trajectories. For example, Chen
et al. (2004) modeled patient immune response using either a linear or quadratic
trajectory. Linear and quadratic models are not appropriate for transplant data, as
neither model can capture a rapid growth or decay in biomarker values. Biomarker
trajectories should be modeled using a more flexible trajectory. Specifically, exponen-
tial trajectories are often a reasonable representation of disease progress (Law et al.,
2002). This exponential growth-decay model can capture the quick increases and
decreases in biomarker values experienced by transplant patients. Non-parametric
models have also been used. Elmi et al. (2011) proposed a B-spline for modeling
longitudinal trajectories. B-splines are particularly useful when all patients are ob-
served at regular intervals. Unfortunately, transplant patients are observed at many
different times which vary from patient to patient. Furthermore, patients tend to
have more observations clustered around the time of transplant. Use of a B-spline
in this situation would therefore require patient-level knots to be used. The model
would be very complex, both computationally and intuitively.
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A popular choice for modeling non-normal patient dropout is a Cox proportional
hazards model (Wu and Carroll, 1988; Law et al., 2002; Yu et al., 2004; Liu et al.,
2004; Tsiatis and Davidian, 2004). Cox models allow the researcher to estimate haz-
ard ratios, relative risks, and odds ratios without requiring assumptions to be made
about patients’ baseline hazards (Cox, 1972). Wulfsohn and Tsiatis (1997) proposed
a linear process with subject-specific random slopes and intercepts for the longitudi-
nal trajectories, and a Cox model for survival times. As with the methods discussed
above, the authors assumed that the random effects were normally distributed. The
proposed longitudinal model is
Y i = α0i + α1iui + ei (2.2.7)
where ei ∼ N (0, σ2!I i), ui is the vector of observation times for subject i, and α0i
and α1i follow a subject-specific bivariate normal distribution. Thus,α0i
α1i
 ∼ N

α0
α1
 , s2αI2
 (2.2.8)
This is a slight extension of the longitudinal models proposed by Schluchter (1992) and
De Gruttola and Tu (1994). Wulfsohn and Tsiatis (1997) modeled the longitudinal
trajectories as fixed values measured with error. Patient survival times are analyzed
using a Cox proportional hazard model.
λ (t) = λ0 (t) exp (ζ (α0i + α1it)) (2.2.9)
19
The two models above lead to the following observed data likelihood:
Lobs =
n∏
i=1
[∫ ∞
−∞
(
mi∏
j=1
φ (yij | αi)
)
× [λ0 (ti) exp (ζ (α0i + α1iti))]δi=1 exp
(
−
∫ ti
0
λ0 (u) exp (β (α0i + α1iu)) du
)
× φ (αi)
]
(2.2.10)
where ti is the minimum of survival and censoring time, δi is an indicator of death
or censoring, and φ (·) is the normal PDF. n and mi are the number of subjects and
observations per subject, respectively.
Simple Cox regression models do not adequately model the survival processes of trans-
plant patients, however. Cox models assume that the likelihood of death increases as
the study progresses, which is clearly not the case with patients who receive some sort
of treatment intervention (Cox, 1972). It is reasonable to suspect that the probability
of death for a patient who receives a treatment would be lower than that of a patient
who does not receive a treatment. We must allow for this change in survival probabil-
ities in our analysis. One method of doing this would be to use a cure model (Baker,
1978). Cure models assume that there are latent “cured” and “susceptible” groups.
Given a treatment, patients in the cured group experience a quick improvement in
health and are classified as “long-term survivors”. Susceptible patients may or may not
die over the course of the study. Though cure models do accommodate the possibility
of a change in death risk post-transplant, they ignore two key features of transplant
data. First, patients who receive transplants can indeed die post-transplant. Second,
not every patient in the study will receive a transplant.
Other proposed models for patient dropout include discrete dropout times (Wu and
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Carroll, 1988) and a logistic dropout process (Elmi, 2009). These models are not
appropriate for transplant data, as the data contains continuous survival times.
2.3. Conclusion
In this chapter, we have discussed the issue of informative dropout in longitudi-
nal studies. We have presented two classes of methods for dealing with informative
dropout: pattern mixture models and selection models. We also discussed the history
and evolution of the shared parameter model (a special case of a selection model).
The methods discussed in this chapter do not allow for all of the issues associated with
transplant data. A valid model for transplant data would need to incorporate non-
linear longitudinal trajectories which could differ pre- and post-transplant, survival
probabilities which differ pre- and post-transplant, and a link that connects the pre-
and post-transplant models. No such model currently exists.
In the following chapters, we will develop a model that compensates for the particular
issues presented by transplant data.
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CHAPTER 3
A Joint Longitudinal-Survival Model with
Post-Transplant Cure
3.1. Introduction
Data from transplant patients have many interesting and unique characteristics. The
data often contain both repeated longitudinal measurements as well as patient survival
information. Unfortunately, studies using this kind of data often focus on either the
longitudinal measurements (e.g., Karam et al., 2003) or patient survival (e.g. Gonwa
et al., 1995). However, it has been shown that longitudinal and survival information
are not independent (Kim et al., 2008). Ignoring the informative link between the two
types of data can lead to biased parameter estimates, or, in extreme cases, incorrect
inference (Diggle et al., 2002). Joint modeling should be used to analyze transplant
data. Linking longitudinal and survival information allows for better inference. In this
chapter, we develop a joint longitudinal-survival model that incorporates both patient
survival information and longitudinal health trajectories. We use liver transplant data
(discussed in Section 1.2) from the United Network of Organ Sharing (UNOS) and
the Hospital of the University of Pennsylvania (HUP) to demonstrate this model.
Many authors have acknowledged the need for joint modeling. For example, Schluchter
(1992); De Gruttola and Tu (1994); Yu et al. (2004); Chen et al. (2004), and Law
et al. (2002) all proposed models for simultaneously analyzing longitudinal and sur-
vival information. These models all incorporated the idea of informative dropout
into their analysis (Tsiatis and Davidian, 2004). There are three factors that must
be considered in developing a joint model: the longitudinal submodel, the survival
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submodel, and the link between the two submodels.
The model link is important, as it determines how the longitudinal and survival
submodels interact. Authors have proposed a variety of different links. One straight-
forward approach is to include the longitudinal biomarker values as a time-varying
covariate in the survival model (Yu et al., 2004). Unfortunately, this does not allow
for inference to be made about the longitudinal biomarker values (since a covariate
cannot be an outcome). Another approach is to assume that the patients can be
divided into latent classes, with each class having its own survival and longitudinal
models (Chen et al., 2004). This approach groups patients based on some future, un-
known dropout time. This is undesirable if we wish to develop a dynamic prediction
model. Therefore, both of these approaches are inappropriate for transplant data.
We believe that there are random effects that contribute to both the survival and
longitudinal models. We include shared patient-level random effects in both the longi-
tudinal and survival submodels. Law et al. (2002) used a somewhat similar approach.
The authors assumed that patient longitudinal trajectories follow a trajectory gov-
erned by patient-specific, normally-distributed random effects. The patient-specific
biomarker trajectories and the population-averaged expected value of the random ef-
fects were included as covariates in the survival model. Unlike Law et al. (2002), we
assume a mixed-effects model for the longitudinal trajectories. We also do not assume
normality of the random effects. Further, we assume that patients who receive treat-
ment are certainly cured (i.e. for patients who receive transplants, the probability of
survival is 1). (Note that this is not a clinically reasonable assumption. We relax this
assumption in Chapter 4.)
As with standard longitudinal modeling, the options for which longitudinal model to
use depend heavily on the type of data being examined. Ten Have et al. (2000) chose
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an ordinal logistic model to analyze functional status data, while Chen et al. (2004)
used a linear or quadratic model for melanoma data. Based on exploratory data
analysis, we believe that our biomarker data follows a U-shaped (but not quadratic)
trajectory. One option is to model this data non-parametrically using a B-spline as
proposed by Elmi et al. (2011). However, B-splines are computationally intensive and
difficult to interpret. Therefore, we will focus on a mixture of exponentials, similar to
the model proposed by Law et al. (2002). This will allow us to have an interpretable
parametric model.
A variety of survival submodels are also available, though not all are appropriate for
transplant data. Many authors advocate the use of a Cox proportional hazards model
(Cox, 1972; Liu et al., 2004; Law et al., 2002). A Cox model is reasonable for survival
data where each subject has an increasing risk of death as the study progresses.
These models also assume that, were the study to last for an infinite amount of time,
all subjects would die. This assumption is invalid in the case of transplant data.
Subjects have the possibility of receiving a transplant, and likely have a very different
survival mechanism post-transplant than they did pre-transplant. Li et al. (2010);
Law et al. (2002) and Chen et al. (2004) used cure models in their analysis. Cure
models assume that, after receiving a treatment, some patients will be “cured” and
cannot experience death. A simple cure model is still inadequate for transplant data,
however. Cure models assume that all patients receive an intervention, which is not
true of transplant candidates. Therefore, we must develop a modified cure model,
which allows some patient to receive treatment and experience disease cure, while
other patients continue the study untreated and potentially die.
In this chapter, we develop a shared-parameter longitudinal-survival model. Pa-
tient dropout and survival are modeled using a modified cure model. Longitudinal
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biomarker trajectories are modeled using a mixture of exponentials. The two sub-
models are linked by shared random effects that are present in both the longitudinal
trajectory model and the frailty term in the survival model.
We present our model and estimation procedures in Section 3.2. We then demonstrate
our methods in Section 3.4 using data from the combined UNOS/HUP dataset. Fi-
nally, we present a simulation study in Section 3.3.
3.2. Model
Let Y i be the (mi × 1) vector denoting the observed longitudinal outcomes for patient
i = 1, . . . , n, and ui be the corresponding observation times. Let ti be the observed
failure time for patient i, where ti is the minimum of Ti, the true survival time,
and Ci, the censoring time. As is standard practice, we define an event indicator
δi = I (Ti ≤ Ci).
A second indicator, τi, represents whether or not a patient receives a transplant. It is
defined as 1 (for patients who receive transplants) and 0 otherwise. tTXi is the time
of transplant for patient i, where applicable. For patients who received transplants,
ti and tTXi are equivalent.
3.2.1. Submodels
We assume that each patient has a biomarker trajectory represented by a non-linear
random-effects exponential decay-growth process similar to the one originally pro-
posed by Law et al. (2002). We modify the model slightly by including both random
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and fixed effects, rather than just random effects, in the longitudinal model.
Y i (ui) = (X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)) + "i (3.2.1)
where "i ∼ N (0, σ2!I) and exp (rji) follows a gamma distribution that will depend on
the linking process used. α is a (p× 1) vector of fixed effects. rji is the j = 1, . . . , 4
random effect for patient i.
The pre-transplant amplitude parameter, β1, is interpreted as the average baseline
starting value for the biomarker measurements. The parameters α and r1i are ad-
ditional fixed effects and random effects, respectively, that determine a subject’s
deviation from the overall population average. Similarly, β3 and r3i are the fixed and
random components of the instantaneous change in biomarker values brought on by
a patient receiving a transplant. The parameters β2 and β4 are population-averaged
growth/decay terms. Random effects r2i and r4i that are of the same signs as β2
and β4 indicate that a patient’s biomarker values are changing at a faster rate than
the expected population average. Conversely, random effects of opposite signs as the
population parameters indicate that a patient’s biomarker values are changing at a
slower rate than the overall population’s.
For the survival portion of our model, we use a cure model similar to the one proposed
by Li et al. (2010):
Si (uik) =

pii, τi = 1, uik ≥ tTXi
(1− pii) exp (−uikbi exp (Xωiζω)) , otherwise
(3.2.2)
Unlike Li et al. (2010), we assume that patients who received transplants are cer-
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tainly cured and cannot experience a decline in health. Therefore, patients receiving
transplants have a cure probability of 1 (i.e. pii = 1.)
We define
bi = γ1 exp (r1i) + γ2 exp (r2i) (3.2.3)
as a subject-specific frailty which links the longitudinal and survival submodels. This
frailty is influenced by both the amplitude and growth rate of a patient’s biomarker
trajectory. We assume γ1 + γ2 = 1 so that we can interpret γ1 and γ2 as weighting
factors. These weights represent the relative influence of pre-transplant longitudinal
amplitude and growth rate on patient frailty. This also ensures that bi = 1 when
r1i = r2i = 0 (meaning the frailty has no influence on the survival probability). The
survival parameter, ζω, is a set of linear predictors that affects a patient’s likelihood of
death prior to transplant. Larger values of ζω indicate a higher probability of death.
Similarly to Li et al. (2010), we require bi ∼ Γ (θ−1, θ−1). By the properties of the
gamma distribution, it follows that exp (rji) ∼ Γ
(
γj
θ ,
θ
γj
)
. We can then derive the
distribution of rji using a change of variables. Let exp (rji) = Rji, so rji = log (Rji) =
g (Rji). Let fR (Rji) be the distribution of Rji. The derivation of the distribution of
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rji, h (rji) follows.
h (rji) =
∣∣∣∣ ddrji (g−1 (Rji))
∣∣∣∣ · fR (g−1 (Rji))
=
∣∣∣∣ ddrji (exp (rji))
∣∣∣∣ · fR (exp (rji))
= exp (rji) · (exp (rji))
γj
θ −1 exp
(− exp (rji) γjθ )(
θ
γj
)γj
θ
Γ
(γj
θ
)
=
(exp (rji))
γj
θ(
θ
γj
) γj
θ
exp
(γj
θ exp (rji)
)
Γ
(γj
θ
) (3.2.4)
Recall that γ3 and γ4 are present in our longitudinal submodel. These parameters have
a similar interpretation as γ1 and γ2. However, they are related to post-transplant
outcomes (of interest in Chapter 4). This model does not investigate post-transplant
survival. Thus, γ3 and γ4 are not estimated here and will be arbitrarily set to 0.4 and
0.6, respectively. Since these parameters are ultimately integrated out of the model
during estimation, the arbitrary values do not appreciably affect the estimated values
of the other model parameters.
3.2.2. Estimation
Parameter estimates are obtained using an EM-based algorithm. The EM algorithm
uses the complete-data likelihood to find the maximum likelihood estimates in the
M-step and the expectations of the sufficient statistics in the E-step.
For simplicity’s sake, we divide our likelihood into three portions, each corresponding
to a different set of patient outcomes.
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1. Patient receives a transplant (τi = 1, δi = 0)
Lτi=1,δi=0 = S
( (ti | ri,Xi) g (Y i | X i, ri)h (ri | X i) (3.2.5)
2. Patient does not receive a transplant, but death is not observed (τi = 0, δi = 0)
Lτi=0,δi=0 = S
∗ (ti | ri,Xi) g (Y i | X i, ri)h (ri | X i) (3.2.6)
3. Patient does not receive a transplant, and death is observed (τi = 0, δi = 1)
Lτi=0,δi=1 = λ
∗ (ti | ri)S∗ (ti | X i, ri) g (Y i | X i, ri)h (ri | X i) (3.2.7)
where
S( (ti | ri,X i) = exp (−tibi exp (Xωiζω))
g (Y i | X i, ri) = 1
(2pi)m/2 (σ2! )
1/2
exp
[
− 1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
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h (ri | X i) =
 2∏
j=1
(exp (rji))
γj
θ(
θ
γj
) γj
θ
exp
(γj
θ exp (rji)
)
Γ
(γj
θ
)

×
 4∏
j=3
(exp (rji))
γj
θ(
θ
γj
) γj
θ
exp
(γj
θ exp (rji)
)
Γ
(γj
θ
)

I(τi=1)
λ∗ (ti | ri) = bi exp (Xωiζω)
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Combining (3.2.5), (3.2.6), and (3.2.7) gives us our full complete-data likelihood.
L =
n∏
i=1
[
Lτi=1,δi=0
I(τi=1)I(δi=0)Lτi=0,δi=0
I(τi=0)I(δi=0)Lτi=0,δi=1
I(τi=0)I(δi=1)
]
=
n∏
i=1
 exp (−tibi exp (Xωiζω))
× [bi exp (Xωiζω)]δi=1
× 1
(2pi)m/2 (σ2! )
1/2
exp
[
− 1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
×
 2∏
j=1
(exp (rji))
γj
θ(
θ
γj
)γj
θ
exp
(γj
θ exp (rji)
)
Γ
(γj
θ
)

×
 4∏
j=3
(exp (rji))
γj
θ(
θ
γj
)γj
θ
exp
(γj
θ exp (rji)
)
Γ
(γj
θ
)

I(τi=1)
 (3.2.8)
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This gives us the following complete-data log-likelihood:
l =
n∑
i=1
{
−tibi exp (Xωiζω)
+ I (δi = 1) (log bi +Xωiζω)
− m
2
log (2pi)− 1
2
log σ2! −
1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
)
+
2∑
j=1
[
γj
θ
rji − γjθ exp (rji)−
γj
θ
log
(
θ
γj
)
− logΓ
(γj
θ
)]
+ I (τi = 1)
4∑
j=3
[
γj
θ
rji − γjθ exp (rji)−
γj
θ
log
(
θ
γj
)
− log Γ
(γj
θ
)]}
(3.2.9)
For the M-step of the algorithm, we can use the principles of maximum likelihood to
determine closed-form estimates for α, β, and σ2! .
The most straightforward way to derive the estimate for α is to note that our model
can be re-parameterized with respect to α. Let
Y ∗i = Y i −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
and
X∗i = 1− exp (− (β2 + r2i)ui)
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Then
Y ∗i = (X
∗
iα)
T + "i (3.2.10)
We apply standard formulas for ordinary least squares regression to (3.2.10) and
obtain the following parameter estimate for α.
αˆ =
1
n
n∑
i=1
E
[(
(X∗i )
T X∗i
)−1
X∗iY
∗
i
]
=
1
n
n∑
i=1
E
[[
((1− exp (− (β2 + r2i)ui))X i)T ((1− exp (− (β2 + r2i)ui))X i)
]−1
× ((1− exp (− (β2 + r2i)ui))X i)T
× (Y i − (β1 + r1i) exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
(3.2.11)
Solving for β1 is also very simple. First, we simplify the complete-data log-likelihood.
lα,β = − 12σ2!
· 1
n
n∑
i=1
[
1
mi
mi∑
k=1
[
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
]2]
+ Cα.β
(3.2.12)
where Cα,β represents all the parts of the log-likelihood that do not contain α or β.
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We then calculate the partial derivative of (3.2.12) with respect to β1.
∂lα,β
∂β1
∝ 1
n
n∑
i=1
[
1
mi
mi∑
k=1
[
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
]
◦ exp ((β2 + r2i)ui)
]
(3.2.13)
where a ◦ b is the Hadamard product of vectors a and b. Setting (3.2.13) equal to
zero and solving for β1, we find the parameter estimate for β1.
βˆ1 =
1
n
n∑
i=1
E
[
1
mi
mi∑
k=1
[[
Y i − (X iα)T
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
]
◦ exp ((β2 + r2i)ui)− r1i + (X iα)T
]]
(3.2.14)
The parameter estimate for β2 is slightly more complicated to calculate, but can still
be done rather easily. We first take the partial derivative of (3.2.12) with respect to
β2.
∂lα,β
∂β2
∝ 1
n
n∑
i=1
[
1
mi
mi∑
k=1
[
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
]
◦
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
]
(3.2.15)
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Setting (3.2.15) equal to zero and solving for β2 gives us
βˆ2 =
1
n
n∑
i=1
E
[
1
mi
mi∑
k=1
log
[
1
ui ◦
(
β1 + r1i − (X iα)T
)
exp (−r2iui)
(
Y i − (X iα)T
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]]
(3.2.16)
Similar approaches are used to solve for β3 and β4 estimates.
βˆ3 =

1∑
I (τi = 1)
n∑
i=1
E
[
1∑
I (ui ≥ tTXi)
mi∑
k=1
[(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
)
× exp (− (β4 + r4i)ui)− r3i
]]
, τi = 1
0, otherwise
(3.2.17)
βˆ4 =

1∑
I (τi = 1)
n∑
i=1
E
[
1∑
I (ui ≥ tTXi)
×
mi∑
k=1
log
[
1
ui ◦ (β3 + r3i) exp (r4iui)
×(Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
)]]
, τi = 1
0, otherwise
(3.2.18)
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Although we have closed-form estimates for all of the longitudinal submodel param-
eters, estimates for α, β2, and β4 are calculated via the fminsearch function in
MATLAB. The fminsearch algorithm finds the minimum of a multivariable func-
tion using unconstrained nonlinear optimization. It is more computationally stable
than using the closed-form estimates directly, due to the relationship between the
closed-form estimates and observation times. We use fminsearch to solve
[
αˆ, βˆ2, βˆ4
]T
= argmin E [lα,β (α, β2, β4)] (3.2.19)
Calculating all parameter estimates via fminsearch would be overly time-consuming.
Therefore, estimates for β1 and β3 will be calculated using (3.2.14) and (3.2.17).
We estimate variance by subtracting subject-level expected values from subject ob-
served values.
σˆ2! =
1
n
n∑
i=1
1
mi
(Y i − E [Y i]) (Y i − E [Y i])T (3.2.20)
where
E [Y i] = E
[
(X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
]
Estimates for γ, ζω, and θ cannot be derived in a closed form. We will approxi-
mate them using the MATLAB fmincon function (which uses constrained nonlinear
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optimization) to solve
[
γˆ1, γˆ2, ζˆω, θˆ
]T
= argmin E [lγ,ζω ,θ (γ1, γ2, ζω, θ)] (3.2.21)
where
lγ,ζω ,θ =
n∑
i=1
{
−tibi exp (Xωiζω)
+ I (δi = 1) (log bi +Xωiζω)
+
2∑
j=1
[
γj
θ
rji − γj
θ
exp (rji)− γj
θ
log
(
θ
γj
)
− log Γ
(γj
θ
)]
+ I (τi = 1)
4∑
j=3
[
γj
θ
rji − γjθ exp (rji)−
γj
θ
log
(
θ
γj
)
− log Γ
(γj
θ
)]}
(3.2.22)
The E-step will evaluate the following integral:
E [f (ri)] =
∫ ∞
0
∫ ∞
0
∫ ∞
0
∫ ∞
0
f (ri) h (ri) dr1idr2idr3idr4i (3.2.23)
where f (ri) is any sufficient statistic. Expanding equations (3.2.14) and (3.2.17)
gives us the following sufficient statistics:
r1i r3i
exp (r2iui) exp (−r4iui)
exp (r2iui) exp (r4iui) exp (−r2iui) exp (−r4iui)
r3i exp (r2iui) exp (r4iui) r1i exp (−r2iui) exp (−r4iui)
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We will use adaptive Gaussian quadrature (AGQ) to determine the numerical value of
(3.2.23) (Pinheiro and Chao, 2006). This method requires integration over a normal
distribution. Since our random effects are not normally distributed, we the standard-
ization methods proposed in Liu and Yu (2008). The resulting integral is
E [f (ri)] =
∫ ∞
−∞
∫ ∞
−∞
∫ ∞
−∞
∫ ∞
−∞
(
f (ri)
h (ri)
φ (ri)
)
φ (ri) dr1idr2idr3idr4i (3.2.24)
where φ (ri) is a standard multivariate normal distribution for ri.
It is clearly not tractable to solve (3.2.24) analytically, so we will approximate it with
the following sum:
E [f (ri)] ≈
∑
k
∑
k
∑
k
∑
k
[f (ri,k) h
∗ (ri,k) w1kw2kw3kw4k] (3.2.25)
where wjk is the kth weight for the j = 1, . . . , 4 random effect and h∗ (ri,k) =
h(ri,k)
φ(ri,k)
.
3.3. Simulations
Simulations were done to evaluate model performance under a variety of conditions.
These conditions varied the percentage of patients who received transplants. Datasets
were simulated under each condition, with each containing 500 patients. Data were
simulated in the following manner:
1. Exponentiated subject-specific random effects were calculated using a gamma
distribution, where
exp (rji) ∼ Γ
(
γj
θ
,
θ
γj
)
j = 1, . . . , 4
Subject-specific random effects were calculated by taking the natural log of the
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exponentiated random effects, i.e. rji = log (exp (rji)).
2. Patient-specific pre-transplant frailties were calculated
bi = γ1 exp (r1i) + γ2 exp (r2i)
3. Pre-transplant survival times were simulated using the methods proposed by
Bender et al. (2005)
Ti = − logU
bi exp (Xωiζω)
where U is a standard uniform random variable
4. A random sample of patients who would be “offered” transplants was deter-
mined.
τi ∼ Binomial (n, pTx)
where pTx is the percentage of patients who will be offered transplants. Subject-
specific transplant times were calculated, so that tTXi = 0.99× Ti
5. Patient survival/censoring status was determined
[ti, δi] =

[min (Ti, Cend) , Ti ≤ Cend] , τi = 0
[tTXi , 0] , τi = 1
where Cend is the end time of the study
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6. Longitudinal data was simulated for all subjects
yik =

[
(X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i) uik)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i)
× exp ((β4 + r4i) (uik − tTXi)) + σ2!
]
, τi = 1
(X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i) uik) , τi = 0, uik ≤ ti
missing, otherwise
Some simulations also utilized “independent” data. Longitudinal data were simulated
using an independent mixed-effects exponential growth-decay model. Survival data
were simulated using a Cox model that was unlinked to the longitudinal model.
Using the data simulated under a joint model, we compared the results of our joint
model to the results of a fully-independent model. We assumed a transplant rate
of 20%. The fully-independent model separately fitted a mixed-effects exponential
growth-decay model to all of the longitudinal data, and a Cox proportional hazard
model to the pre-transplant survival data. Results of the simulations are shown in
Table 3.1. Longitudinal parameter estimates are relatively unbiased, regardless of
whether a joint or independent model is used. This is to be expected. Liu (2011)
show that fixed (i.e. not time-varying) estimates will be fairly unbiased even when
analysis is done using a correctly-specified mixed-effects independent model. Survival
estimates are similar on average in both models.
Using data simulated under an independent model, we compare our joint model to
an independent model. Data were simulated assuming that 50% of patients received
transplants. Results are shown in Table 3.2. Again, estimates for the longitudinal
40
Table 3.1: Simulation results for joint vs. indep. model, when joint model is true
Joint model Independent model
Parameter Truth Est. (SE) Est. (SE)
α1 0.1 0.10 (0.0001) 0.10 (0.0001)
α2 2 2.03 (0.007) 2.03 (0.007)
β1 6 6.00 (0.0007) 6.00 (0.0007)
β2 0.5 0.49 (0.001) 0.49 (0.001)
β3 -2 -2.00 (0.003) -2.00 (0.003)
β4 0.2 0.21 (0.003) 0.21 (0.003)
γ1 0.2 0.19 (0.001) 0.19 (0.001)
γ2 0.8 0.81 (0.001) 0.81 (0.001)
θ 0.03 0.03 (0.0002) 0.03 (0.0002)
ζω -2 -2.15 (0.02) -2.01 (0.02)
σ2! 1 1.00 (0.001) 1.00 (0.001)
trajectory parameters are relatively unbiased for both models. Our new joint model
over-estimated the fixed-effect survival parameters. This is to be expected, since the
model is misspecified.
The results of a comparison of model performance under a variety of conditions are
shown in Table 3.3. Simulation results show that the longitudinal submodel does
reasonably well across all conditions. The quality of the pre-transplant survival esti-
mates deteriorates as the percentage of patients receiving transplants increases. This
is understandable, since we have assumed that patients who receive transplants can-
not die. Therefore, a high proportion of patients receiving transplants implies that
only a small amount of pre-transplant survival information is available.
A more complicated model does not make much of a difference in the quality of param-
eter estimation when we are only interested in pre-transplant survival. The end goal of
this dissertation, however, is to draw conclusions about both pre- and post-transplant
survival times, while incorporating information from longitudinal biomarker values.
Therefore, proper estimation of survival parameters is very important. In this chap-
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Table 3.2: Simulation results for joint vs. indep. model, when indep. model is true
Joint model Independent model
Parameter Truth Est. (SE) Est. (SE)
α1 0.1 0.10 (0.0001) 0.10 (0.0001)
α2 2 2.04 (0.007) 2.04 (0.007)
β1 6 6.00 (0.0007) 6.00 (0.0007)
β2 0.5 0.49 (0.001) 0.49 (0.001)
β3 -2 -2.00 (0.002) -2.00 (0.002)
β4 0.2 0.21 (0.002) 0.21 (0.002)
γ1 0.2 0.19 (0.001) 0.19 (0.001)
γ2 0.8 0.81 (0.001) 0.81 (0.001)
θ 0.03 0.03 (0.0002) 0.03 (0.0002)
ζω -2 -2.54 (0.05) -1.76 (0.03)
σ2! 1 1.00 (0.001) 1.00 (0.001)
Table 3.3: Simulation results for model performance across varying conditions
20% Tx 50% Tx 90% Tx
Parameter Truth Est. (SE) Est. (SE) Est. (SE)
α1 0.1 0.10 (0.0001) 0.10 (0.0001) 0.10 (0.0001)
α2 2 2.03 (0.007) 2.04 (0.006) 2.05 (0.008)
β1 6 6.00 (0.0007) 6.00 (0.0008) 6.00 (0.0007)
β2 0.5 0.49 (0.001) 0.49 (0.001) 0.49 (0.002)
β3 -2 -2.00 (0.003) -2.00 (0.002) -2.00 (0.002)
β4 0.2 0.21 (0.003) 0.21 (0.002) 0.21 (0.002)
γ1 0.2 0.19 (0.001) 0.19 (0.001) 0.19 (0.003)
γ2 0.8 0.81 (0.001) 0.81 (0.001) 0.81 (0.003)
θ 0.03 0.03 (0.0002) 0.03 (0.0002) 0.03 (0.0004)
ζω -2 -2.15 (0.02) -2.54 (0.04) -4.49 (0.33)
σ2! 0.25 1.00 (0.001) 1.00 (0.002) 1.00 (0.001)
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ter, we demonstrate that our model performs equally as well as an independent model.
In Chapter 4, we will examine the implications of ignoring pre-transplant survival and
biomarker information when making inferences about post-transplant survival.
3.4. Application
The United Network of Organ Sharing (UNOS) registry collects data on every patient
who is on the waiting list for an organ transplant. Patient history, baseline, and
demographic variables are recorded at the time of waitlisting. Updates to the registry
occur with varying frequency (based on organ, illness severity, and other factors).
Patients who receive a transplant will also have an entry in the UNOS registry.
Liver transplant patients have their records updated every time they receive an update
to their Model for End-stage Liver Disease (MELD) score. MELD scores have been
used to rank waitlisted patients since February 27, 2002. Law requires that MELD
scores are updated more often for sicker patients (UNOS, 2002), which could cause
bias in statistical inference. In an attempt to avoid this potential bias, we merged
UNOS data with data from the Hospital of the University of Pennsylvania (HUP).
The resulting dataset had more observations per subject, regardless of disease severity.
An in-depth discussion of the motivations and creation of the UNOS/HUP dataset
can be found in Section 1.2.
In this chapter, we assume that patients who receive transplants are definitely cured
and therefore cannot die. Table 3.4 shows the percentage of death and censoring, as
well as average follow-up and survival times. Patients were followed for a maximum of
five years (1826 days) post-waitlisting. Our analytic dataset (referred to as Subset 1)
consisted of 500 patients waitlisted for a liver transplant at HUP between February,
27, 2002, and May, 13, 2011. Approximately 30% of our patients received transplants
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Table 3.4: Descriptive statistics for UNOS/HUP Subset 1
Tx group No Tx group Total
n (%) 171 (34) 329 (66) 500
Number censored (%) 171 (100) 231 (70) 402 (80)
Number dead (%) - 98 (30) -
Mean follow-up time 3.1 years 2.5 years 2.7 years
Median time to Tx 5.9 months - -
Median observable survival time! - 5.0 years -
Male gender (%) 114 (67) 248 (75) 362 (72)
Mean age at WLing (years) 53.7 52.6 53.0
! - Due to censoring, the median observed survival time is equal to the maximum survival time
during this timeframe, with a median waiting time of 6.5 months. Of the patients
who did not receive transplants, approximately 30% were observed to have died by
the end of the study. Average follow-up time for all subjects was 2.7 years, with
transplanted patients having longer follow-up times than those who did not have a
transplant (3.1 vs. 2.5 years). Demographics (gender and age at waitlisting) were
similar for both groups.
Transplant data has unique characteristics that must be considered when forming a
statistical model (see Section 1.1). Figure 3.1 illustrates some of these characteris-
tics. Sicker patients (indicated by higher bilirubin levels) may be more likely to be
removed from the waitlist or die. In addition, we expect that patients who receive a
transplant will see an improvement in health and a lower likelihood of death. Visual
comparison between patients who did and did not die show that survivors who did
not receive transplants tend to have lower, steadier bilirubin levels. Patients with
drastic increases in their bilirubin levels (or those who are waitlisted with higher
levels initially) are more likely to either die or receive a transplant. This highlights
the possibility of informative dropout. Patients who receive transplants also have a
noticeable improvement in liver function (as indicated by a drop in bilirubin levels)
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Figure 3.1: Bilirubin trajectories (UNOS/HUP Subset 1)
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post-transplant.
We model this data using the methods developed in Section 3.2. For this analysis, we
include age at waitlisting and gender as linear terms in the longitudinal submodel and
gender as the explanatory variable in the survival submodel. A set of 100 bootstraps
were run to determine standard errors for the estimates (Efron, 1982). Results from
15 of the bootstraps were excluded from the calculations in Table 3.5 due to outliers in
the parameter estimates. Results indicate that age at waitlisting does not significantly
affect bilirubin levels (0.53 mg/dL increase in bilirubin level for each additional year;
95% CI = [-1.55,2.61]). Male gender has a small, but significant, effect on bilirubin
values (0.16 mg/dL higher than women; 95% CI = [0.10,0.22]).
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Table 3.5: Data analysis results for UNOS/HUP Subset 1
Joint model Independent model
Parameter Est. (Bootstrap SE) Est. (Bootstrap SE)
α1 (age at WLing) 0.53 (1.06) 0.56 (1.04)
α2 (male gender) 0.16 (0.03) 0.16 (0.03)
β1 3.42 (0.02) 3.42 (0.02)
β2 -0.79 (0.05) -0.79 (0.05)
β3 54.11 (102.33) 46.33 (99.18)
β4 -9.89 (9.70) -9.91 (9.37)
γ1 0.20 (0.001) 0.20 (0.009)
γ2 0.80 (0.001) 0.80 (0.009)
θ 0.08 (0.005) 0.07 (0.005)
ζω (male gender) -0.70 (0.007) -0.07 (0.02)
σ2! 13.09 (0.25) 13.09 (0.24)
The remaining longitudinal parameter estimates show an overall average bilirubin
level of 3.42 mg/dL at waitlisting (95% CI = [3.38,3.46]). Patients who do not receive
transplants have increasing bilirubin levels, as indicated by the negative value of β2.
This is reasonable, since patients are expected to become more ill as their time on the
waiting list increases. For this data, post-transplant trajectories are not significantly
different from pre-transplant trajectories. The estimates for β3 and β4 are both non-
significant. Our results show that male transplant recipients are less likely to die on
the waiting list (hazard ratio = exp (−0.70) = 0.50). This agrees with the findings of
Moylan et al. (2008). (Mindikoglu et al. (2010) note that this disparity may actually
be due to differences in kidney function. Though this warrants further investigation,
our data do not allow for proper consideration of the effect of kidney function.)
We also fitted independent longitudinal and survival models to the data in order to
assess the sensitivity of the results to the model link. The independent model gives
a highly attenuated estimate for pre-transplant survival. This indicates that, under
“real world” conditions, the implications of using a joint model versus an independent
model are even more pronounced than in idealized simulations.
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3.5. Discussion
In this chapter, we have developed a joint longitudinal-survival model that incor-
porates patient cure post-transplant. This model combines a non-linear exponential
growth-decay model with a modified cure model in order to investigate the relation-
ship between longitudinal trajectories (both pre- and post-transplant) and survival
times pre-transplant. We assume that all patients who receive transplants are cured.
This model does well under a variety of circumstances. We also show that the model
performs as well as an independent model. This result is key to the extensions that
will be presented in Chapter 4.
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CHAPTER 4
A Joint Longitudinal-Survival Model with Possible
Post-Transplant Death
4.1. Introduction
Data from transplant patients has many characteristics that can make it difficult to
model properly. To investigate both patient survival and longitudinal health trajecto-
ries, we must overcome the “standard” issues with both kinds of models: non-random
dropout in longitudinal and survival studies, proportional hazards or distributional
assumptions about survival times, etc. (Diggle et al., 2002; Cox, 1972). In addition,
it is reasonable to suspect that there is some sort of link between patients’ longitudi-
nal trajectories and survival processes. It is not sufficient to model the longitudinal
trajectories and survival times with independent models. Failing to acknowledge the
potential link could lead to biased parameter estimates and possibly incorrect infer-
ence (Diggle et al., 2002). We must incorporate the presence of non-random dropout
(or “informative missingness”) into our analysis (Little and Rubin, 1987). To do this,
we need to use a joint longitudinal-survival model (discussed in detail in Chapter 2).
The need for joint modeling has been acknowledged by researchers in fields other than
transplantation. Yu et al. (2004); Chen et al. (2004) and Law et al. (2002) developed
joint models for dealing with informative dropout. These authors propose models
with a variety of different submodels and model links. The choice of longitudinal and
survival submodels, as well as the choice of model link, depends on the type of study
data.
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Many different longitudinal models have been considered. Methods have been de-
veloped for both continuous and non-continuous data. Ten Have et al. (2000) used
an ordinal logistic model to analyze ordinal functional status data. For continuous
data, parametric and non-parametric models have been proposed (Chen et al., 2004;
Elmi et al., 2011; Law et al., 2002). The model developed by Chen et al. (2004)
can be used for linear or quadratic data. A more complex parametric exponential
growth-decay model was proposed by Law et al. (2002). Elmi et al. (2011) used a
non-parametric B-spline to model labor and delivery data. None of these models
fully address the features of transplant data. Non-continunous models are clearly not
appropriate for continunous biomarkers. Linear and quadratic models do not cap-
ture the quick increases and decreases that occur in transplant patients’ biomarker
values. B-splines can capture these dynamic features. However, B-splines can be
computationally intensive and difficult to interpret. A useful model for longitudinal
biomarkers in transplant data is the exponential growth-decay process proposed by
Law et al. (2002). This model can incorporate exponential increases and decreases in
biomarker values, as well as an immediate drop in values post-transplant. Law et al.
(2002)’s model is not entirely appropriate, however, so we will modify Law et al.
(2002)’s model slightly. We remove the assumption of normally-distributed random
effects. We also include both fixed and random effects in our longitudinal model.
((Law et al., 2002) treats patient longitudinal trajectory effects as random.)
The informative dropout process is often assumed to be a survival process (Liu et al.,
2004; Law et al., 2002; Chen et al., 2004), though it can be any dichotomous outcome.
Elmi (2009) proposed a logistic model for the dropout process. Most often, though,
authors use a Cox proportional hazards model to analyze patient survival times.
Law et al. (2002) and Chen et al. (2004) modified the Cox model to incorporate the
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possibility of patient cure. Standard Cox models assume a decreasing probability of
death (Cox, 1972). This assumption is not appropriate in the case of transplant data,
since we expect patients to have a change in health post-transplant. Cure models
allow for this change in hazard of death (Baker, 1978). Cure models are not entirely
adequate for transplant data, however. These models assume that all patients receive
a treatment, and that those who are “cured” cannot die from the disease being treated.
Not all waitlisted patients will receive transplants, and not all patients who receive
transplant will survive long-term. Therefore, we take the “spirit” of a cure model and
adapt it to include two different Cox models – one for pre-transplant survival and one
for post-transplant survival. The two Cox models are related via a frailty term that
appears in both models.
The link between the longitudinal and survival models determines how the survival
process and longitudinal trajectories affect one another. A simple way to link the two
models is to include the longitudinal trajectories as a time-varying covariate in the
survival model (Yu et al., 2004). Though this is straightforward, it does not allow
us to explicitly model the longitudinal process as an outcome. If the longitudinal
outcome is of interest, patients can be divided into latent classes with class-specific
longitudinal and survival models (Chen et al., 2004). However, it is not possible to
determine a patient’s class ahead of time. Therefore, it is more appropriate to model
transplant data using a shared parameter model, where patient-level random effects
are present in both the longitudinal and survival models. (Shared parameter models
are discussed in detail in Section 2.2.)
In this chapter, we extend the joint model proposed in Chapter 3. We link an ex-
ponential growth-decay longitudinal submodel to a modified cure submodel using
patient-level random effects. We then demonstrate our model using liver transplant
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data from the United Network of Organ Sharing (UNOS) and the Hospital of the
University of Pennsylvania (HUP) in Section 4.4. (This dataset is discussed in detail
in Section 1.2.)
4.2. Model
For this model, we use the same variables described in Section 3.2, with some small
additions. We add in another patient-level design matrix, Xpii, which is associated
with a patient’s post-transplant survival. We also modify our assumptions regarding
the distribution of the random effects.
4.2.1. Submodels
As in Chapter 3, we assume that each patient has a biomarker trajectory represented
by a non-linear exponential decay-growth process similar to the model proposed by
Law et al. (2002).
Y i (ui) = (X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)) + "i (4.2.1)
where "i ∼ N (0, σ2!I). α is a (p× 1) vector of fixed effects. rji, the j = 1, . . . , 4
random effect for patient i, is assumed to be log-gamma distributed.
The interpretation of the longitudinal submodel parameters is discussed in Section
3.2. The first amplitude parameter, β1, is the overall population average bilirubin level
at time of waitlisting. The linear term, α, represents how an individual’s covariate
values affect his initial bilirubin level. The second amplitude parameter, β3, is the
average change in bilirubin levels post-transplant. The exponential rate terms, β2
and β4, are the growth rates pre- and post-transplant, respectively.
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We change our proposed survival model by incorporating the possibility of patient
death post-transplant. Thus,
Si (uik) =

exp (− (uik − tTXi) b2i exp (Xpiiζpi)) , τi = 1, uik ≥ tTXi
exp (−uikb1i exp (Xωiζω)) , otherwise
(4.2.2)
where
b1i = γ1 exp (r1i) + γ2 exp (r2i)
b2i = cb1i + (1− c) (γ3 exp (r3i) + γ4 exp (r4i))
As in Section 3.2, ζω is a set of parameters that affect pre-transplant survival. Sim-
ilarly, ζpi is a set of linear predictors that are related to patients’ post-transplant
survival probabilities. The frailties b1i and b2i influence pre- and post-transplant
survival functions, respectively. The post-transplant frailty, b2i, incorporates b1i in
the post-transplant survival function. The weighting parameter, c, determines the
relative effect of pre- and post-transplant random effects on post-transplant survival.
The change in the survival model gives us a more clinically-relevant model, as it
allows for the possibility of post-transplant death. For patients who do not receive a
transplant, a single Cox model represents their survival times. Patients who receive
transplants have a survival function that changes at the time of transplant. The
frailty in the second survival model, b2i, links pre- and post-transplant survival by
combining the pre-transplant frailty with post-transplant random effects.
As in Chapter 3, we place distributional restrictions on b1i and b2i. We assume
b1i ∼ Γ (θ−1, θ) and b2i ∼ Γ
(
(cθ)−1 , cθ
)
. By the properties of the gamma distribution,
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it follows that
exp (r1i) ∼ Γ
(
1
2θ
,
θ
γ1
)
exp (r2i) ∼ Γ
(
1
2θ
,
θ
γ2
)
exp (r3i) ∼ Γ
(
1− c
2cθ
,
cθ
(1− c) γ3
)
exp (r4i) ∼ Γ
(
1− c
2cθ
,
cθ
(1− c) γ4
)
Therefore,
h (rji) =

(exp(rji))
1
2θ(
θ
γj
) 1
2θ
exp(
γj
θ exp(rji))Γ(
1
2θ )
, j = 1, 2
(exp(rji))
1−c
2cθ(
cθ
(1−c)γj
) 1−c
2cθ
exp
(
(1−c)γj
cθ exp(rji)
)
Γ( 1−c2cθ )
, j = 3, 4
(4.2.3)
4.2.2. Estimation
Parameter estimates are obtained using an EM-based algorithm. The EM algorithm
uses the complete-data likelihood to find the maximum likelihood estimates in the
M-step and the expectations of the sufficient statistics in the E-step.
For simplicity’s sake, we divide our likelihood into four portions, each corresponding
to a different set of patient outcomes.
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1. Patient receives a transplant, and death is not observed (τi = 1, δi = 0)
Lτi=1,δi=0 = S
(
Tx (ti | ri,Xi) g (Y i | X i, ri)h (ri | X i) hTx (ri | X i) (4.2.4)
2. Patient receives a transplant, and death is observed (τi = 1, δi = 1)
Lτi=1,δi=1 = λ
∗
Tx (ti | ri)S∗Tx (ti | X i, ri) g (Y i | X i, ri)h (ri | X i) hTx (ri | X i)
(4.2.5)
3. Patient does not receive a transplant, and death is not observed (τi = 0, δi = 0)
Lτi=0,δi=0 = S
∗ (ti | ri,Xi) g (Y i | X i, ri)h (ri | X i) (4.2.6)
4. Patient does not receive a transplant, and death is observed (τi = 0, δi = 1)
Lτi=0,δi=1 = λ
∗ (ti | ri)S∗ (ti | X i, ri) g (Y i | X i, ri)h (ri | X i) (4.2.7)
where
S( (ti | ri,X i) = exp (−tib1i exp (Xωiζω))
λ∗ (ti | ri) = b1i exp (Xωiζω)
S(Tx (ti | ri,X i) = exp (− (ti − tTXi) b2i exp (Xpiiζpi)) exp (−tTXib1i exp (Xωiζω))
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λ∗Tx (ti | ri) = b2i exp (Xpiiζpi)
g (Y i | X i, ri) = 1
(2pi)m/2 (σ2! )
1/2
exp
[
− 1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
h (ri | X i) = h (r1i)h (r2i)
hTx (ri | X i) = h (r3i)h (r4i)
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Combining (4.2.4), (4.2.5), (4.2.6), and (4.2.7) gives us our full complete-data likeli-
hood.
L =
n∏
i=1
[
Lτi=1,δi=0
I(τi=1)I(δi=0)Lτi=1,δi=1
I(τi=1)I(δi=1)Lτi=0,δi=0
I(τi=0)I(δi=0)
× Lτi=0,δi=1I(τi=0)I(δi=1)
]
=
n∏
i=1
 (exp (−tib1i exp (Xωiζω)))I(τi=0)
×
[
exp (−tTXib1i exp (Xωiζω)) exp (− (ti − tTXi) b2i exp (Xpiiζpi))
]I(τi=1)
× [b1i exp (Xωiζω)]τi=0,δi=1
× [b2i exp (Xpiiζpi)]τi=1,δi=1
× 1
(2pi)m/2 (σ2! )
1/2
exp
[
− 1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
×
 2∏
j=1
(exp (rji))
1
2θ(
θ
γj
) 1
2θ
exp
(γj
θ exp (rji)
)
Γ
(
1
2θ
)

×
 4∏
j=3
(exp (rji))
1−c
2cθ(
cθ
(1−c)γj
) 1−c
2cθ
exp
(
(1−c)γj
cθ exp (rji)
)
Γ
(
1−c
2cθ
)

I(τi=1)
 (4.2.8)
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This gives us the following complete-data log-likelihood:
l =
n∑
i=1
{
−I (τi = 0) tib1i exp (Xωiζω)
− I (τi = 1) [tTXib1i exp (Xωiζω) (ti − tTXi) b2i exp (Xpiiζpi)]
+ I (τi = 0, δi = 1) [log b1i +Xωiζω]
+ I (τi = 1, δi = 1) [log b2i +Xpiiζpi]
− m
2
log (2pi)− 1
2
log σ2! −
1
2σ2!
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
)T
×
(
Y i − (X iα)T −
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
)
+
2∑
j=1
[
1
2θ
rji − γj
θ
exp (rji)− 1
2θ
log
(
θ
γj
)
− logΓ
(
1
2θ
)]
+ I (τi = 1)
4∑
j=3
[
1− c
2cθ
rji − (1− c) γjcθ exp (rji)−
1− c
2cθ
log
(
cθ
(1− c) γj
)
− logΓ
(
1− c
2cθ
)]}
(4.2.9)
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Parameter estimates are calculated in the same way as (3.2.11), (3.2.14), (3.2.16),
(3.2.17), and (3.2.18) in Section 3.2. Therefore, the longitudinal parameter estimates
are
αˆ =
1
n
n∑
i=1
E
[(
(X∗i )
T X∗i
)−1
X∗iY
∗
i
]
=
1
n
n∑
i=1
E
[[
((1− exp (− (β2 + r2i)ui))X i)T ((1− exp (− (β2 + r2i)ui))X i)
]−1
× ((1− exp (− (β2 + r2i)ui))X i)T
× (Y i − (β1 + r1i) exp (− (β2 + r2i)ui)
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]
(4.2.10)
βˆ1 =
1
n
n∑
i=1
E
[
1
mi
mi∑
k=1
[(
Y i − (X iα)T
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)
× exp ((β2 + r2i)ui)− r1i + (X iα)T
]]
(4.2.11)
βˆ2 =
1
n
n∑
i=1
E
[
1
mi
mi∑
k=1
log
[
1
ui ◦
(
β1 + r1i − (X iα)T
)
exp (−r2iui)
×
(
Y i − (X iα)T
− I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
)]]
(4.2.12)
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βˆ3 =

1∑
I (τi = 1)
n∑
i=1
E
[
1∑
I (ui ≥ tTXi)
mi∑
k=1
[(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
)
× exp (− (β4 + r4i)ui)− r3i
]]
, τi = 1
0, otherwise
(4.2.13)
βˆ4 =

1∑
I (τi = 1)
n∑
i=1
E
[
1∑
I (ui ≥ tTXi)
×
mi∑
k=1
log
[
1
ui ◦ (β3 + r3i) exp (r4iui)
×
(
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
)]]
, τi = 1
0, otherwise
(4.2.14)
Estimates for α, β2, and β3 are calculated using numerical approximation techniques,
due to the relationship between the closed-form estimates and observation times.
We use MATLAB’s fminsearch function (an unconstrained nonlinear optimization
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routine) to solve
[
αˆ, βˆ2, βˆ4
]T
= argmin E [lα,β (α, β2, β4)] (4.2.15)
where
lα,β = − 12σ2!
· 1
n
n∑
i=1
[
1
mi
mi∑
k=1
[
Y i − (X iα)T
−
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
− (I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi)))
]2]
+ Cα.β
(4.2.16)
and Cα,β represents all the parts of the log-likelihood that do not contain α or β.
(Note that this is the same equation as (3.2.12).)
Calculating all parameter estimates via fminsearch would be overly time-
consuming. Therefore, as in Chapter 3, estimates for β1 and β3 will be calculated
using (4.2.11) and (4.2.13).
We estimate variance by subtracting subject-level expected values from subject ob-
served values.
σˆ2! =
1
n
n∑
i=1
1
mi
(Y i − E [Y i]) (Y i − E [Y i])T (4.2.17)
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where
E [Y i] = E
[
(X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i)ui)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i) exp ((β4 + r4i) (ui − tTXi))
]
Estimates for γ, ζω, ζpi, and θ cannot be derived in a closed form. We will approximate
them using the fmincon function in MATLAB to solve
[
γˆ, ζˆω, ζˆpi, θˆ, cˆ
]T
= argmin E [lγ,ζω ,ζpi,θ,c (γ, ζω, ζpi, θ, c)] (4.2.18)
where
lγ,ζω ,ζpi,θ,c =
n∑
i=1
{
−I (τi = 0) tib1i exp (Xωiζω)
− I (τi = 1) (tTXib1i exp (Xωiζω) (ti − tTXi) b2i exp (Xpiiζpi))
+ I (τi = 0, δi = 1) (log b1i +Xωiζω)
+ I (τi = 1, δi = 1) (log b2i +Xpiiζpi)
+
2∑
j=1
[
1
2θ
rji − γj
θ
exp (rji)− 1
2θ
log
(
θ
γj
)
− log Γ
(
1
2θ
)]
+ I (τi = 1)
4∑
j=3
[
1− c
2cθ
rji − (1− c) γjcθ exp (rji)
− 1− c
2cθ
log
(
cθ
(1− c) γj
)
− log Γ
(
1− c
2cθ
)]}
(4.2.19)
fmincon is similar to fminsearch, except that it uses constrained nonlinear optimiza-
tion to solve a scalar function.
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As in Chapter 3, the E-step will evaluate the following integral:
E [f (ri)] =
∫ ∞
0
∫ ∞
0
∫ ∞
0
∫ ∞
0
f (ri) h (ri) dr1idr2idr3idr4i (4.2.20)
where f (ri) is any sufficient statistic. Expanding (4.2.11) and (4.2.13) gives us the
following sufficient statistics:
r1i r3i
exp (r2iui) exp (−r4iui)
exp (r2iui) exp (r4iui) exp (−r2iui) exp (−r4iui)
r3i exp (r2iui) exp (r4iui) r1i exp (−r2iui) exp (−r4iui)
We will use adaptive Gaussian quadrature (AGQ) to determine the numerical value of
(4.2.20) (Pinheiro and Chao, 2006). This method requires integration over a normal
distribution. Since our random effects are not normally distributed, we the standard-
ization methods proposed in Liu and Yu (2008). The resulting integral is:
E [f (ri)] =
∫ ∞
−∞
∫ ∞
−∞
∫ ∞
−∞
∫ ∞
−∞
(
f (ri)
h (ri)
φ (ri)
)
φ (ri) dr1idr2idr3idr4i (4.2.21)
where φ (ri) is a standard multivariate normal distribution for ri.
It is clearly not tractable to solve (4.2.21) analytically, so we will approximate it with
the following sum:
E [f (ri)] ≈
∑
k
∑
k
∑
k
∑
k
[f (ri,k) h
∗ (ri,k) w1kw2kw3kw4k] (4.2.22)
where wjk is the kth weight for the j = 1, . . . , 4 random effect and h∗ (ri,k) =
h(ri,k)
φ(ri,k)
.
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4.3. Simulations
To investigate the performance of our model, we analyzed 100 simulated datasets,
with a sample size of n = 500 each. The model was tested under three different con-
ditions, and compared to an independent model (where longitudinal, pre-transplant
survival, and post-transplant survival were all considered independent of one another).
Subjects were followed for five years after waitlisting and were required to have at
least two observations pre- and post-transplant (with a minimum of four observations
total).
Data simulations involved several steps:
1. Exponentiated subject-specific random effects were calculated using a gamma
distribution, where
exp (rji) ∼ Γ
(
1
2θ
,
θ
γj
)
j = 1, 2
exp (rji) ∼ Γ
(
1− c
2cθ
,
cθ
(1− c) γj
)
j = 3.4
Subject specific random effects were calculated by taking the natural log of the
exponentiated random effects, i.e. rji = log (exp (rji)).
2. Patient-specific pre-transplant frailties were calculated
b1i = γ1 exp (r1i) + γ2 exp (r2i)
3. Pre-transplant survival times were simulated using the methods proposed by
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Bender et al. (2005)
Ti = − logUb1i exp (Xωiζω)
where U is a standard uniform random variable
4. A random sample of patients who would be “offered” transplants was deter-
mined.
τi ∼ Binomial (n, pTx)
where pTx is the percentage of patients who will be offered transplants. Subject-
specific transplant times were calculated, so that tTXi = 0.99× Ti
5. Patient pre-transplant survival/censoring status was determined for patients
who did not receive transplants
[ti, δi] = [min (Ti, Cend) , Ti ≤ Cend]
where Cend is the end time of the study
6. Post-transplant survival/censoring times were determined for patients who re-
ceived transplants using a similar process as described above
(a) Patient-specific post-transplant frailties were calculated
b2i = cb1i + (1− c) (γ3 exp (r3i) + γ4 exp (r4i))
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(b) Post-transplant survival times were simulated
T Txi = −
logU
b2i exp (Xpiiζpi)
+ tTXi
(c) Patient post-transplant survival/censoring status was determined
[ti, δi] =
[
min
(
T Txi , Cend
)
, T Txi ≤ Cend
]
7. Longitudinal data was simulated for all subjects
yik =

[
(X iα)
T +
(
β1 + r1i − (X iα)T
)
exp (− (β2 + r2i) uik)
+ I (τi = 1, ui ≥ tTXi) (β3 + r3i)
× exp ((β4 + r4i) (uik − tTXi)) + σ2!
]
, uik ≤ ti
missing, otherwise
Data simulated from a joint model were used to compare the joint model results with
that of an independent model, as in Chapter 3. Results of the simulations are shown
in Table 4.1. As in Chapter 3, we see that the model generally does well estimating
the longitudinal trajectory parameters, and again is not very different from the in-
dependent model. This is to be expected in models with no time-varying covariates
(Liu, 2011). On average, the joint model performs better when estimating post-
transplant survival, while the independent model performs better when estimating
pre-transplant survival. The mean bias difference in pre-transplant survival estimates
is small, though. On average, the independent model pre-transplant estimates have
a 0.76% lower bias than the joint model estimates. The joint model has advantages
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Table 4.1: Simulation results for joint vs. indep. model, when joint model is true
Joint model Independent model
Parameter Truth Est. (SE) Est. (SE)
α1 0.3 0.29 (0.0004) 0.29 (0.0004)
α2 3.5 3.40 (0.03) 3.42 (0.03)
β1 4 4.02 (0.01) 4.00 (0.01)
β2 -0.1 -0.10 (0.0003) -0.10 (0.0003)
β3 -4 -3.83 (0.05) -3.87 (0.05)
β4 -1 -0.98 (0.005) -0.99 (0.004)
γ1 0.55 0.56 (0.0008) 0.56 (0.0007)
γ2 0.4 0.38 (0.0004) 0.39 (0.0004)
γ3 0.25 0.26 (0.002) 0.26 (0.002)
γ4 0.2 0.21 (0.001) 0.21 (0.001)
θ 0.03 0.02 (0.0003) 0.02 (0.0004)
c 0.75 0.79 (0.003) 0.78 (0.003)
ζω -2 -2.14 (0.009) -1.92 (0.01)
ζpi -3 -3.16 (0.16) -3.24 (0.17)
σ2! 1 1.13 (0.02) 1.17 (0.02)
over the independent model when estimating post-transplant survival parameters.
For post-transplant survival, the joint model estimates have about 3% less bias than
the independent model estimates. Sharing information across the submodels clearly
improves our estimation abilities.
Data were also simulated assuming independent submodels. These data were used to
compare the joint model results with that of an independent model. It is important
to note that it is impossible to simulate fully-independent data. Patients who receive
transplants must always survive to transplant. Therefore, pre- and post-transplant
survival are inevitably linked. This implies that both the joint model and the fully-
independent model are misspecified. We present the fully-independent results in order
to compare our model against “standard practice.”
Results of the simulations are shown in Table 4.2. Results from one of the simulations
were excluded from the calculations in Table 4.2 due to outliers in the parameter
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Table 4.2: Simulation results for joint vs. indep. model, when indep. model is true
Joint model Independent model
Parameter Truth Est. (SE) Est. (SE)
α1 0.3 0.29 (0.0005) 0.29 (0.0005)
α2 3.5 3.36 (0.02) 3.35 (0.02)
β1 4 4.12 (0.01) 4.09 (0.02)
β2 -0.1 -0.10 (0.0005) -0.10 (0.0005)
β3 -4 -3.82 (0.10) -3.90 (0.10)
β4 -1 -0.99 (0.003) -0.99 (0.003)
γ1 0.55 0.56 (0.001) 0.57 (0.001)
γ2 0.4 0.37 (0.0005) 0.38 (0.0005)
γ3 0.25 0.26 (0.001) 0.26 (0.001)
γ4 0.2 0.21 (0.0006) 0.21 (0.0006)
θ 0.03 0.02 (0.0002) 0.02 (0.0003)
c 0.75 0.77 (0.002) 0.78 (0.002)
ζω -2 -2.83 (0.02) -1.33 (0.02)
ζpi -3 -2.99 (0.03) -2.30 (0.03)
σ2! 1 1.19 (0.03) 1.24 (0.03)
estimates. We see that the longitudinal parameter estimates are generally unbiased
for both the joint and independent models. Pre-transplant survival estimates are
biased for both the independent and joint models, which is to be expected, since both
models are misspecified. Bias is also present in the independent model post-transplant
survival estimates. In contrast, the joint model produces unbiased post-transplant
survival estimates, even under a misspecified model.
Another simulation was done to compare the performance of the model under various
conditions, as defined by the number of patients who receive transplants. Results of
that simulation are shown in Table 4.3. Longitudinal parameter values are estimated
well in all simulated situations. Some differences in the pre-transplant survival pa-
rameter estimates appear as the percentage of transplanted patients increase. This
is due to the relative lack of pre-transplant information under those conditions. It is
also important to note that a transplant percentage of 90% is unreasonable clinically.
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Table 4.3: Simulation results for model performance across varying conditions
20% Tx 50% Tx 90% Tx
Parameter Truth Est. (SE) Est. (SE) Est. (SE)
α1 0.3 0.29 (0.0004) 0.29 (0.0004) 0.29 (0.0006)
α2 3.5 3.40 (0.03) 3.37 (0.03) 3.33 (0.02)
β1 4 4.02 (0.009) 4.04 (0.008) 4.08 (0.017)
β2 -0.1 -0.10 (0.0003) -0.10 (0.0003) -0.10 (0.0005)
β3 -4 -3.83 (0.05) -3.76 (0.04) -3.82 (0.06)
β4 -1 -0.98 (0.005) -0.98 (0.001) -0.99 (0.003)
γ1 0.55 0.56 (0.0008) 0.56 (0.0009) 0.56 (0.0012)
γ2 0.4 0.38 (0.0004) 0.38 (0.0006) 0.37 (0.0008)
γ3 0.25 0.26 (0.002) 0.26 (0.001) 0.26 (0.001)
γ4 0.2 0.20 (0.0010) 0.21 (0.0007) 0.21 (0.0005)
θ 0.03 0.02 (0.0003) 0.02 (0.0003) 0.02 (0.0003)
c 0.75 0.79 (0.003) 0.79 (0.002) 0.79 (0.002)
ζω -2 -2.14 (0.009) -2.59 (0.02) -4.18 (0.04)
ζpi -3 -3.16 (0.16) -2.93 (0.03) -2.84 (0.02)
σ2! 1 1.13 (0.02) 1.10 (0.01) 1.16 (0.03)
Percentages ranging from 20-50% are much more reasonable.
4.4. Application
In this chapter, we modify the assumptions made in Chapter 3 to include the possi-
bility of post-transplant death. Descriptive statistics for this dataset (referred to as
Subset 2) are found in Table 4.4. Patients were followed for a maximum of five years
(1826 days) post-waitlisting, or three years (1096 days) post-transplant, whichever
was shorter. The analysis dataset contained 500 patients who were waitlisted for a
liver transplant at HUP between February, 27, 2002, and May, 13, 2011. Approxi-
mately 30% of our patients received transplants during this timeframe. Of the patients
who did not receive transplants, approximately 30% were observed to have died by
the end of the study. Of the patients who did receive transplants, approximately
13% were observed to have died within three years of transplant. Average follow-up
time for all subjects was 2.2 years, with transplanted patients having longer follow-up
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Table 4.4: Descriptive statistics for UNOS/HUP Subset 2
Tx group No Tx group Total
n (%) 166 (33) 334 (67) 500
Number censored (%) 144 (87) 244 (73) 388 (78)
Number dead (%) 22 (13) 90 (27) 112 (22)
Mean follow-up time 2.6 years 2.0 years 2.2 years
Median time to Tx 5.6 months - -
Median observable survival time! 4.7 years 5 years 5 years
Male gender (%) 117 (71) 223 (67) 340 (68)
Mean age at WLing (years) 51.6 53.2 52.7
! - Due to censoring, the median observed survival time is equal to the maximum survival time
times than those who did not receive a transplant (2.6 vs. 2.0 years). Median time to
transplant was 5.6 months. Median survival times could not be accurately calculated
due to censoring. Demographics (gender and age at waitlisting) were similar for both
groups.
As discussed in Section 1.1, transplant data has many characteristics that pose chal-
lenges with statistical modeling. Figure 4.1 highlights some of these characteristics.
Prior to transplant, patients who have a spike in bilirubin levels (indicating a wors-
ening of disease), are more likely to die or receive a transplant. Post-transplant, a
similar pattern holds. Patients who experience a large spike in bilirubin levels post-
transplant are more likely to die. These spikes prior to either transplant or death
indicate that patients are not dying or being offered transplanted in a random fash-
ion. Sicker patients appear to be more likely to receive transplants or die. The
exponential growth-decay model lets us capture this increase in bilirubin values pre-
transplant, as well as the immediate drop and exponential decrease post-transplant.
Modifying a standard cure model to include both a pre- and post-transplant Cox sur-
vival model allows us to analyze survival times pre- as well as post-transplant. The
shared random effects in the model link the longitudinal biomarker values to pre- and
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Figure 4.1: Bilirubin trajectories (UNOS/HUP Subset 2)
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post-transplant survival.
Results for our data analysis are shown in Table 4.5. Standard errors were calculated
via 100 bootstrap iterations (Efron, 1982). Results from one of the bootstraps were
excluded from the calculations in Table 4.5 due to outliers in the parameter estimates.
As in Section 3.4, we include both gender and age at waitlisting as covariates in the
longitudinal model. Gender alone is a covariate in both the pre- and post-transplant
survival models. Our results show that male gender and age at waitlisting are signif-
icantly related to patient bilirubin values. Males and older individuals have higher
bilirubin values (3.97 mg/dL, 95% CI = [3.32,4.62]; and 0.26 mg/dL/year, 95% CI
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Table 4.5: Data analysis results for UNOS/HUP Subset 2
Joint model Independent model
Parameter Est. (Bootstrap SE) Est. (Bootstrap SE)
α1 (male gender) 3.97 (0.33) 3.99 (0.32)
α2 (age at WLing) 0.26 (0.006) 0.26 (0.006)
β1 4.08 (0.04) 4.09 (0.04)
β2 -0.13 (0.001) -0.13 (0.001)
β3 -4.37 (0.11) -4.34 (0.12)
β4 -1.01 (0.02) -1.01 (0.02)
γ1 0.55 (0.0001) 0.55 (0.0001)
γ2 0.43 (0.0003) 0.43 (0.0003)
γ3 0.24 (0.0007) 0.24 (0.0007)
γ4 0.21 (0.0004) 0.21 (0.0004)
θ 0.005 (0.0001) 0.005 (0.0001)
c 0.96 (0.0008) 0.96 (0.0008)
ζω (male gender) -2.25 (0.01) -0.10 (0.02)
ζpi (male gender) -2.96 (0.03) -0.34 (0.18)
σ2! 16.69 (0.36) 16.70 (0.35)
= [0.25,0.27], respectively). Estimates for β1 and β2 indicate that patients have an
average bilirubin level of 4.08 mg/dL at waitlisting, and that patients experience
an average gradual increase in bilirubin levels pre-transplant (growth rate = 0.13
mg/dL). Estimates of post-transplant parameters β3 and β4 indicate that patients
experience a drop in bilirubin levels of 4.37 mg/dL post-transplant, followed by a
decrease over time (growth rate = -1.01 mg/dL).
Survival parameter estimates indicate that males are significantly less likely than
females to die both pre- and post-transplant (hazard ratio = 0.11 and 0.05, respec-
tively.) This confirms analyses done by Mindikoglu et al. (2010) and Hariharan et al.
(2002), where the authors found higher survival rates for males on the waiting list
and post-transplant.
A comparison of the joint model results with those from a fully-independent “stan-
dard practice” analysis reveals an interesting result. Estimates for both pre- and
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post-transplant survival are drastically attenuated. Futhermore, the independent
model gives non-significant results for post-transplant survival. This highlights the
importance of carefully choosing an inference method, as conclusions can differ across
methods.
4.5. Discussion
In this chapter, we modified the model proposed in Chapter 3 to include the possi-
bility of post-transplant death. We again use an exponential growth-decay curve to
represent patient longitudinal trajectories. We change the survival function by adding
in a second Cox model for patient survival post-transplant. We have shown that this
model does reasonably well under varying conditions defined by different transplant
percentages. Post-transplant survival estimates are improved in our model as com-
pared with the independent model.
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CHAPTER 5
Conclusion
In this dissertation, we introduce a joint longitudinal-survival model. This model is
developed to address the complex and underappreciated statistical issues presented
by data from transplant patients. We review the history and issues associated with
transplant data in Chapter 1. In Chapter 2, we discuss the problem of informative
dropout and the models used to compensate for it.
In Chapter 3, we propose an exponential growth-decay longitudinal submodel and a
modified cure submodel to investigate pre-treatment survival times. These submodels
are linked by shared random effects that appear in both patients’ longitudinal trajec-
tories and their pre-transplant survival frailties. Patients who receive transplants are
assumed to be “cured” and cannot die during the study. We demonstrate our model
using liver transplant data from the United Network of Organ Sharing (UNOS) and
the Hospital of the University of Pennsylvania (HUP). Serum total bilirubin is our
longitudinal outcome, with age at waitlisting and gender being considered as covari-
ates in the submodels. Simulations show that our model is more efficient than a Cox
model for estimating parameters related to patient survival.
In Chapter 4, we extend our model to include the possibility of post-transplant patient
death. To do this, we modify the cure submodel to contain two Cox models, one for
pre-transplant survival and another for post-transplant survival. We continue to
model the longitudinal trajectories using an exponential growth-decay curve. The
longitudinal and survival submodels are linked by shared random effects, which are
present in patient-specific longitudinal trajectories as well as in the frailties of the two
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Cox models. We again apply our methods to liver transplant data from UNOS and
HUP. We consider patients’ serum total bilirubin values as the longitudinal outcome of
interest. Pre- and post-transplant survival times are investigated as well. Our model
shows an improvement in the estimation of the survival parameters, as compared with
an independent model. An important future goal of this work is to predict patient
survival times; therefore, it is critical that our proposed joint model performs better
than an independent model when determining estimates for survival parameters.
Many opportunities exist for extending this model. Future directions are primarily
aimed at developing a model that is more clinically relevant and useful to patients.
Proposed extensions include:
1. Multivariate outcomes
Multivariate outcomes are of interest since one biomarker alone may not ade-
quately capture a patient’s health status. Specifically, we know that liver trans-
plant patients’ MELD scores are made up of three different biomarkers: serum
total bilirubin, serum creatinine, and INR. Though the MELD score is not vali-
dated post-transplant, these biomarkers are likely still relevant post-transplant
(e.g. Wu et al., 2010).
2. Repeated events
Liu et al. (2004) developed a joint model that considers the effect of a recurrent
event (hospitalization) on a terminal event (death). This is of obvious value in
a transplant setting, where patients may experience a variety of repeated events
of interest (e.g. hospitalization, acute rejection, infection). Terminal events to
consider could be death or re-transplant.
3. Value censoring
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Value censoring happens when observations are missing due to exceeding some
threshold. This can happen when biomarker values are above or below some
detectable limit (Wu, 2004). For example, MELD scores are value-censored by
UNOS, as they are capped at 40. Statistically, this problem is dealt with via a
Tobit model (Tobin, 1958).
4. Multiple types of transplant
Different types of transplants are available to patients. Organs can come from
“standard criteria” donors (SCD) or from “expanded criteria” donors (ECD).
ECD organs have characteristics that may make them associated with poorer
outcomes than SCD organs (Metzger et al., 2003). Patients can also receive
organs from donors with an increased risk of viral infection (called CDC organs).
There is debate as to whether or not the extra risk associated with ECD and
CDC organs is of practical significance, considering the long wait times for
transplants(Amin et al., 2004; Reese et al., 2009).
5. Predictive model / Point-and-click software
A predictive model would be of most use for clinicians. Rizopoulos (2011) pro-
posed a model for dynamic prediction relating longitudinal CD4 counts to a
patient’s probability of death. A similar model (that incorporates any or all
of the above extensions) could be developed and could be of great use clin-
ically, particularly if point-and-click software were made available (de Leeuw
and Zeileis).
The models presented in this dissertation are a decided improvement on standard
independent and joint analysis methods. The methods we propose allow for more
accurate and precise estimation of factors that affect patient survival times after
being placed on the liver transplant waiting list. These models provide us with the
75
tools needed to properly analyze patient data from the time of waitlisting, past the
time of transplant, and on to possible post-transplant death. Extensions of these
models could be used to create effective clinical tools that would be used to counsel
patients on their healthcare options.
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APPENDIX
Abbreviations
NOTA National Organ Transplant Act
OPTN Organ Procurement and Transplantation Network
UNOS United Network of Organ Sharing
HUP Hospital of the University of Pennsylvania
MELD Model for End-Stage Liver Disease
Cr Serum creatinine
TBIL Total serum bilirubin
INR International normalized ratio (of prothrombin time)
Tx Transplant
WL Waitlisting
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Table of Notation
Variable Dimension Description
Y i mi × 1 Subject-specific longitudinal measures
ui mi × 1 Subject-specific observation times
α p× 1 Fixed effects for longitudinal model
Σ = σ2! I mi ×mi Covariance matrix for longitudinal measures
X i m× p Covariates for fixed effects
ζpi ppi × 1 Fixed effects for subject-specific probability of death
post-transplant (Chapter 4)
Xpii ppi × 1 Covariates for probability of death post-transplant
(Chapter 4)
ζω pω × 1 Fixed effects for subject-specific probability of death
pre-transplant
Xωi pω × 1 Covariates for probability of death pre-transplant
ri 4× 1 Subject-specific random effects
γ 4× 1 Fixed effects relating subject-specific random effects
to subject-specific frailty
ti 1× 1 Subject survival time
bi 1× 1 Subject-specific pre-transplant frailty (Chapter 3)
b2i 1× 1 Subject-specific pre-transplant frailty (Chapter 4)
b1i 1× 1 Subject-specific post-transplant frailty (Chapter 4)
c 1× 1 Weighting factor that relates pre- and post-transplant
survival (Chapter 4)
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